Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other Working Capital Changes (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Other Working Capital Changes for 6 consecutive years, with -$357000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Working Capital Changes rose 59.11% to -$357000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$954000.0, a 12.32% increase, with the full-year FY2024 number at -$1.4 million, down 72.36% from a year prior.
  • Other Working Capital Changes was -$357000.0 for Q3 2025 at Vivos Therapeutics, down from $301000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.3 million in Q2 2021 to a low of -$873000.0 in Q3 2024.
  • A 5-year average of -$85277.8 and a median of -$146500.0 in 2023 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 28424.88% in 2021; the steepest drop was 22468.42% in 2021.
  • Vivos Therapeutics' Other Working Capital Changes stood at -$210000.0 in 2021, then skyrocketed by 146.19% to $97000.0 in 2022, then plummeted by 257.73% to -$153000.0 in 2023, then crashed by 226.14% to -$499000.0 in 2024, then rose by 28.46% to -$357000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Other Working Capital Changes are -$357000.0 (Q3 2025), $301000.0 (Q2 2025), and -$399000.0 (Q1 2025).